Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$190 Mln
P/E Ratio
--
P/B Ratio
1.67
Industry P/E
--
Debt to Equity
0
ROE
-0.74 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.23
CFO
$-192.17 Mln
EBITDA
$-235.62 Mln
Net Profit
$-248.76 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Rezolute Inc. (NV) (RZLT)
| -18.78 | 30.49 | -17.26 | 12.43 | 6.44 | -0.10 | -24.31 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Rezolute Inc. (NV) (RZLT)
| 387.07 | -52.03 | -56.69 | -60.13 | 108.52 | 27.78 | -89.70 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is... in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Address: 275 Shoreline Drive, Redwood City, CA, United States, 94065 Read more
Founder, CEO & Acting Chairman of the Board
Mr. Nevan Charles Elam J.D.
Founder, CEO & Acting Chairman of the Board
Mr. Nevan Charles Elam J.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Rezolute Inc (NV) (RZLT) stood at $ 123 Mln as on 31-Dec-24
The share price of Rezolute Inc (NV) (RZLT) is $3.98 (NASDAQ) as of 23-Apr-2025 16:28 EDT. Rezolute Inc (NV) (RZLT) has given a return of 6.44% in the last 3 years.
Rezolute Inc (NV) (RZLT) has a market capitalisation of $ 190 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Rezolute Inc (NV) (RZLT) is 1.67 times as on 22-Apr-2025, a 24% discount to its peers’ median range of 2.20 times.
Since, TTM earnings of Rezolute Inc (NV) (RZLT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rezolute Inc (NV) (RZLT) and enter the required number of quantities and click on buy to purchase the shares of Rezolute Inc (NV) (RZLT).
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Address: 275 Shoreline Drive, Redwood City, CA, United States, 94065
The CEO & director of Mr. Nevan Charles Elam J.D.. is Rezolute Inc (NV) (RZLT), and CFO & Sr. VP is Mr. Nevan Charles Elam J.D..
There is no promoter pledging in Rezolute Inc (NV) (RZLT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Rezolute Inc. (NV) (RZLT) | Ratios |
|---|---|
|
Return on equity(%)
|
-64.49
|
|
Operating margin(%)
|
-126224.14
|
|
Net Margin(%)
|
-122644.83
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Rezolute Inc (NV) (RZLT) was $0 Mln.
$0.87
(
